================================================================================
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
SCHEDULE 13D/A
(Rule 13d-102)
INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND
AMENDMENTS THEREFO FILED PURSUANT TO RULE 13d-2(a)
(AMENDMENT NO. 6)
BIOENVISION, INC.
(Name of Issuer)
COMMON STOCK, PAR VALUE $0.001 PER SHARE
(Title of Class of Securities)
09059N100
(CUSIP Number)
ANDREW NICHOLSON
PERSEUS-SOROS BIOPHARMACEUTICAL FUND, LP
888 SEVENTH AVENUE, 30TH FLOOR
NEW YORK, NY 10106
TEL. NO.: (212) 651-6383
(Name, Address and Telephone Number of
Person Authorized
to Receive Notices and Communications)
with a copy to
JOHN C. KENNEDY, ESQ.
PAUL, WEISS, RIFKIND, WHARTON & GARRISON LLP
1285 AVENUE OF THE AMERICAS
NEW YORK, NEW YORK 10019-6064
JULY 10, 2007
(Date of Event which Requires Filing of this Statement)
If the filing person has previously filed a statement on Schedule 13G to report
the acquisition that is the subject of this Schedule 13D, and is filing this
schedule because of Sections 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check
the following box [_].
*The remainder of this cover page shall be filled out for a reporting person's
initial filing on this form with respect to the subject class of securities,
and for any subsequent amendment containing information which would alter
disclosures provided in a prior cover page.
The information required on the remainder of this cover page shall not be
deemed to be "filed" for the purposes of Section 18 of the Securities Exchange
Act of 1934 ("Act") or otherwise subject to the liabilities of that section of
the Act but shall be subject to all other provisions of the Act (however, see
the Notes).
(continued on following pages)
Page 1 of 15 pages)
===============================================================================
CUSIP NO. 09059N100 Page 2 of 15
SCHEDULE 13D
-------------------------------------------------------------------------------
1 NAME OF REPORTING PERSON
I.R.S. IDENTIFICATION NO. OF ABOVE PERSON (ENTITIES ONLY)
Perseus-Soros BioPharmaceutical Fund, LP
-------------------------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(a) [_]
(b) [X]
-------------------------------------------------------------------------------
3 SEC USE ONLY
-------------------------------------------------------------------------------
4 SOURCE OF FUNDS
Not Applicable
-------------------------------------------------------------------------------
5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO
ITEMS 2(d) OR 2(e)
[_]
-------------------------------------------------------------------------------
6 CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware
-------------------------------------------------------------------------------
7 SOLE VOTING POWER
0
NUMBER OF -------------------------------------
SHARES 8 SHARED VOTING POWER
BENEFICIALLY 75,009 (1)
OWNED BY -------------------------------------
EACH 9 SOLE DISPOSITIVE POWER
REPORTING 0
PERSON -------------------------------------
WITH 10 SHARED DISPOSITIVE POWER
75,009 (1)
-------------------------------------------------------------------------------
11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
75,009 (1)
-------------------------------------------------------------------------------
12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES
[_]
-------------------------------------------------------------------------------
13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
0.001%
-------------------------------------------------------------------------------
14 TYPE OF REPORTING PERSON
PN
-------------------------------------------------------------------------------
------------
(1) Assumes exercise of a Warrant to purchase 75,009 shares of Common Stock.
CUSIP NO. 09059N100 Page 3 of 15
SCHEDULE 13D
-------------------------------------------------------------------------------
1 NAME OF REPORTING PERSON
I.R.S. IDENTIFICATION NO. OF ABOVE PERSON (ENTITIES ONLY)
Perseus-Soros Partners, LLC
-------------------------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(a) [_]
(b) [X]
-------------------------------------------------------------------------------
3 SEC USE ONLY
-------------------------------------------------------------------------------
4 SOURCE OF FUNDS
Not Applicable
-------------------------------------------------------------------------------
5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO
ITEMS 2(d) OR 2(e)
[_]
-------------------------------------------------------------------------------
6 CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware
-------------------------------------------------------------------------------
7 SOLE VOTING POWER
0
NUMBER OF -------------------------------------
SHARES 8 SHARED VOTING POWER
BENEFICIALLY 75,009 (1)(2)
OWNED BY -------------------------------------
EACH 9 SOLE DISPOSITIVE POWER
REPORTING 0
PERSON -------------------------------------
WITH 10 SHARED DISPOSITIVE POWER
75,009 (1)(2)
-------------------------------------------------------------------------------
11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
75,009 (1)(2)
-------------------------------------------------------------------------------
12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES
[_]
-------------------------------------------------------------------------------
13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
0.001%
-------------------------------------------------------------------------------
14 TYPE OF REPORTING PERSON
OO
-------------------------------------------------------------------------------
------------
(1) Assumes exercise of a Warrant to purchase 75,009 shares of Common Stock.
(2) Consists of 75,009 shares of Common Stock beneficially owned by
Perseus-Soros Partners, LLC ("Perseus-Soros Partners") solely in its
capacity as sole general partner of Perseus-Soros.
CUSIP NO. 09059N100 Page 4 of 15
SCHEDULE 13D
-------------------------------------------------------------------------------
1 NAME OF REPORTING PERSON
I.R.S. IDENTIFICATION NO. OF ABOVE PERSON (ENTITIES ONLY)
Perseus BioTech Fund Partners, LLC
-------------------------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(a) [_]
(b) [X]
-------------------------------------------------------------------------------
3 SEC USE ONLY
-------------------------------------------------------------------------------
4 SOURCE OF FUNDS
Not Applicable
-------------------------------------------------------------------------------
5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO
ITEMS 2(d) OR 2(e)
[_]
-------------------------------------------------------------------------------
6 CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware
-------------------------------------------------------------------------------
7 SOLE VOTING POWER
0
NUMBER OF -------------------------------------
SHARES 8 SHARED VOTING POWER
BENEFICIALLY 75,009 (1)(2)
OWNED BY -------------------------------------
EACH 9 SOLE DISPOSITIVE POWER
REPORTING 0
PERSON -------------------------------------
WITH 10 SHARED DISPOSITIVE POWER
75,009 (1)(2)
-------------------------------------------------------------------------------
11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
75,009 (1)(2)
-------------------------------------------------------------------------------
12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES
[_]
-------------------------------------------------------------------------------
13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
0.001%
-------------------------------------------------------------------------------
14 TYPE OF REPORTING PERSON
OO
-------------------------------------------------------------------------------
------------
(1) Assumes exercise of a Warrant to purchase 75,009 shares of Common Stock.
(2) Consists of 75,009 shares of Common Stock beneficially owned by Perseus
BioTech Fund Partners, LLC ("Perseus Partners") solely in its capacity as
a managing member of Perseus-Soros Partners, which is the sole general
partner of Perseus-Soros.
CUSIP NO. 09059N100 Page 5 of 15
SCHEDULE 13D
-------------------------------------------------------------------------------
1 NAME OF REPORTING PERSON
I.R.S. IDENTIFICATION NO. OF ABOVE PERSON (ENTITIES ONLY)
SFM Participation, L.P.
-------------------------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(a) [_]
(b) [X]
-------------------------------------------------------------------------------
3 SEC USE ONLY
-------------------------------------------------------------------------------
4 SOURCE OF FUNDS
Not Applicable
-------------------------------------------------------------------------------
5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO
ITEMS 2(d) OR 2(e)
[_]
-------------------------------------------------------------------------------
6 CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware
-------------------------------------------------------------------------------
7 SOLE VOTING POWER
0
NUMBER OF -------------------------------------
SHARES 8 SHARED VOTING POWER
BENEFICIALLY 75,009 (1)(2)
OWNED BY -------------------------------------
EACH 9 SOLE DISPOSITIVE POWER
REPORTING 0
PERSON -------------------------------------
WITH 10 SHARED DISPOSITIVE POWER
75,009 (1)(2)
-------------------------------------------------------------------------------
11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
75,009 (1)(2)
-------------------------------------------------------------------------------
12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES
[_]
-------------------------------------------------------------------------------
13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
0.001%
-------------------------------------------------------------------------------
14 TYPE OF REPORTING PERSON
PN
-------------------------------------------------------------------------------
------------
(1) Assumes exercise of a Warrant to purchase 75,009 shares of Common Stock.
(2) Consists of 75,009 shares of Common Stock beneficially owned by SFM
Participation, L.P. ("SFM Participation") solely in its capacity as a
managing member of Perseus-Soros Partners, which is the sole general
partner of Perseus-Soros.
CUSIP NO. 09059N100 Page 6 of 15
SCHEDULE 13D
-------------------------------------------------------------------------------
1 NAME OF REPORTING PERSON
I.R.S. IDENTIFICATION NO. OF ABOVE PERSON (ENTITIES ONLY)
SFM AH LLC
-------------------------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(a) [_]
(b) [X]
-------------------------------------------------------------------------------
3 SEC USE ONLY
-------------------------------------------------------------------------------
4 SOURCE OF FUNDS
Not Applicable
-------------------------------------------------------------------------------
5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO
ITEMS 2(d) OR 2(e)
[_]
-------------------------------------------------------------------------------
6 CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware
-------------------------------------------------------------------------------
7 SOLE VOTING POWER
0
NUMBER OF -------------------------------------
SHARES 8 SHARED VOTING POWER
BENEFICIALLY 75,009 (1)(2)
OWNED BY -------------------------------------
EACH 9 SOLE DISPOSITIVE POWER
REPORTING 0
PERSON -------------------------------------
WITH 10 SHARED DISPOSITIVE POWER
75,009 (1)(2)
-------------------------------------------------------------------------------
11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
75,009 (1)(2)
-------------------------------------------------------------------------------
12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES
[_]
-------------------------------------------------------------------------------
13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
0.001%
-------------------------------------------------------------------------------
14 TYPE OF REPORTING PERSON
OO
-------------------------------------------------------------------------------
------------
(1) Assumes exercise of a Warrant to purchase 75,009 shares of Common Stock.
(2) Consists of 75,009 shares of Common Stock beneficially owned by SFM AH LLC
("SFM AH") solely in its capacity as the general partner of SFM
Participation, which is a managing member of Perseus-Soros Partners, which
is the sole general partner of Perseus-Soros.
CUSIP NO. 09059N100 Page 7 of 15
SCHEDULE 13D
-------------------------------------------------------------------------------
1 NAME OF REPORTING PERSON
I.R.S. IDENTIFICATION NO. OF ABOVE PERSON (ENTITIES ONLY)
Perseuspur, LLC
-------------------------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(a) [_]
(b) [X]
-------------------------------------------------------------------------------
3 SEC USE ONLY
-------------------------------------------------------------------------------
4 SOURCE OF FUNDS
Not Applicable
-------------------------------------------------------------------------------
5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO
ITEMS 2(d) OR 2(e)
[_]
-------------------------------------------------------------------------------
6 CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware
-------------------------------------------------------------------------------
7 SOLE VOTING POWER
0
NUMBER OF -------------------------------------
SHARES 8 SHARED VOTING POWER
BENEFICIALLY 75,009 (1)(2)
OWNED BY -------------------------------------
EACH 9 SOLE DISPOSITIVE POWER
REPORTING 0
PERSON -------------------------------------
WITH 10 SHARED DISPOSITIVE POWER
75,009 (1)(2)
-------------------------------------------------------------------------------
11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
75,009 (1)(2)
-------------------------------------------------------------------------------
12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES
[_]
-------------------------------------------------------------------------------
13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
0.001%
-------------------------------------------------------------------------------
14 TYPE OF REPORTING PERSON
OO
-------------------------------------------------------------------------------
------------
(1) Assumes exercise of a Warrant to purchase 75,009 shares of Common Stock.
(2) Consists of 75,009 shares of Common Stock beneficially owned by
Perseuspur, L.L.C. ("Perseuspur") solely in its capacity as the managing
member of Perseus Partners, which is a managing member of Perseus-Soros
Partners, which is the sole general partner of Perseus-Soros.
CUSIP NO. 09059N100 Page 8 of 15
SCHEDULE 13D
-------------------------------------------------------------------------------
1 NAME OF REPORTING PERSON
I.R.S. IDENTIFICATION NO. OF ABOVE PERSON (ENTITIES ONLY)
Frank H. Pearl (in the capacity described herein)
-------------------------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(a) [_]
(b) [X]
-------------------------------------------------------------------------------
3 SEC USE ONLY
-------------------------------------------------------------------------------
4 SOURCE OF FUNDS
Not Applicable
-------------------------------------------------------------------------------
5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO
ITEMS 2(d) OR 2(e)
[_]
-------------------------------------------------------------------------------
6 CITIZENSHIP OR PLACE OF ORGANIZATION
United States
-------------------------------------------------------------------------------
7 SOLE VOTING POWER
0
NUMBER OF -------------------------------------
SHARES 8 SHARED VOTING POWER
BENEFICIALLY 75,009 (1)(2)
OWNED BY -------------------------------------
EACH 9 SOLE DISPOSITIVE POWER
REPORTING 0
PERSON -------------------------------------
WITH 10 SHARED DISPOSITIVE POWER
75,009 (1)(2)
-------------------------------------------------------------------------------
11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
75,009 (1)(2)
-------------------------------------------------------------------------------
12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES
[_]
-------------------------------------------------------------------------------
13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
0.001%
-------------------------------------------------------------------------------
14 TYPE OF REPORTING PERSON
IN
-------------------------------------------------------------------------------
------------
(1) Assumes exercise of a Warrant to purchase 75,009 shares of Common Stock.
(2) Consists of 75,009 shares of Common Stock beneficially owned by Mr. Pearl
solely in his capacity as the sole member of Perseuspur, which is the
managing member of Perseus Partners, which is a managing member of
Perseus-Soros Partners, which is the sole general partner of
Perseus-Soros.
CUSIP NO. 09059N100 Page 9 of 15
SCHEDULE 13D
-------------------------------------------------------------------------------
1 NAME OF REPORTING PERSON
I.R.S. IDENTIFICATION NO. OF ABOVE PERSON (ENTITIES ONLY)
Soros Fund Management LLC
-------------------------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(a) [_]
(b) [X]
-------------------------------------------------------------------------------
3 SEC USE ONLY
-------------------------------------------------------------------------------
4 SOURCE OF FUNDS
Not Applicable
-------------------------------------------------------------------------------
5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO
ITEMS 2(d) OR 2(e)
[_]
-------------------------------------------------------------------------------
6 CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware
-------------------------------------------------------------------------------
7 SOLE VOTING POWER
0
NUMBER OF -------------------------------------
SHARES 8 SHARED VOTING POWER
BENEFICIALLY 75,009 (1)(2)
OWNED BY -------------------------------------
EACH 9 SOLE DISPOSITIVE POWER
REPORTING 0
PERSON -------------------------------------
WITH 10 SHARED DISPOSITIVE POWER
75,009 (1)(2)
-------------------------------------------------------------------------------
11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
75,009 (1)(2)
-------------------------------------------------------------------------------
12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES
[_]
-------------------------------------------------------------------------------
13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
0.001%
-------------------------------------------------------------------------------
14 TYPE OF REPORTING PERSON
OO; IA
-------------------------------------------------------------------------------
------------
(1) Assumes exercise of a Warrant to purchase 75,009 shares of Common Stock.
(2) Consists of 75,009 shares of Common Stock beneficially owned by Soros Fund
Management LLC ("SFM LLC") solely in its capacity as the sole managing
member of SFM AH, which is the sole general partner of SFM Participation,
which is a managing member of Perseus-Soros Partners, which is the sole
general partner of Perseus-Soros.
CUSIP NO. 09059N100 Page 10 of 15
SCHEDULE 13D
-------------------------------------------------------------------------------
1 NAME OF REPORTING PERSON
I.R.S. IDENTIFICATION NO. OF ABOVE PERSON (ENTITIES ONLY)
George Soros (in the capacity described herein)
-------------------------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(a) [_]
(b) [X]
-------------------------------------------------------------------------------
3 SEC USE ONLY
-------------------------------------------------------------------------------
4 SOURCE OF FUNDS
Not Applicable
-------------------------------------------------------------------------------
5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO
ITEMS 2(d) OR 2(e)
[_]
-------------------------------------------------------------------------------
6 CITIZENSHIP OR PLACE OF ORGANIZATION
United States
-------------------------------------------------------------------------------
7 SOLE VOTING POWER
0
NUMBER OF -------------------------------------
SHARES 8 SHARED VOTING POWER
BENEFICIALLY 75,009 (1)(2)
OWNED BY -------------------------------------
EACH 9 SOLE DISPOSITIVE POWER
REPORTING 0
PERSON -------------------------------------
WITH 10 SHARED DISPOSITIVE POWER
75,009 (1)(2)
-------------------------------------------------------------------------------
11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
75,009 (1)(2)
-------------------------------------------------------------------------------
12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES
[_]
-------------------------------------------------------------------------------
13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
0.001%
-------------------------------------------------------------------------------
14 TYPE OF REPORTING PERSON
IA
-------------------------------------------------------------------------------
------------
(1) Assumes exercise of a Warrant to purchase 75,009 shares of Common Stock.
(2) Consists of 75,009 shares of Common Stock beneficially owned by Mr. Soros,
Chairman of SFM LLC, which is the sole managing member of SFM AH, which is
the sole general partner of SFM Participation, which is a managing member
of Perseus-Soros Partners, which is the sole general partner of
Perseus-Soros.
CUSIP NO. 09059N100 Page 11 of 15
SCHEDULE 13D
Item 1. SECURITY AND ISSUER.
This Amendment No. 6 to Schedule 13D relates to the common
stock, par value $0.001 per share (the "Common Stock") of Bioenvision, Inc., a
Delaware corporation (the "Company"). This Amendment No. 6 supplementally
amends the initial statement on Schedule 13D, filed with the Securities and
Exchange Commission on May 20, 2002, as amended by Amendment No. 1 filed on
January 8, 2003, Amendment No. 2 filed on May 17, 2004, Amendment No. 3 filed
on December 17, 2004, Amendment No. 4 filed on December 21, 2004, and Amendment
No. 5 filed on May 30, 2007 (collectively, the "Initial Statement"), filed by
the Reporting Persons, and is being filed pursuant to Rule 13d-2 under the
Securities Exchange Act of 1934, as amended (the "Exchange Act"). The address
of the principal executive offices of the Company is 345 Park Avenue, 41st
Floor, New York, New York 10154. Capitalized terms used but not defined herein
shall have the meanings ascribed to them in the Initial Statement. The Initial
Statement is supplementally amended as follows.
Item 2. IDENTITY AND BACKGROUND.
(a) No material change.
(b) No material change.
(c) No material change.
(d) No material change.
(e) No material change.
(f) No material change.
Item 3. SOURCE AND AMOUNT OF FUNDS OR OTHER CONSIDERATION.
No material change.
Item 4. PURPOSE OF TRANSACTION.
ITEM 4 IS HEREBY AMENDED BY ADDING THE FOLLOWING AT THE END
THEREOF:
The Offer contemplated by the Merger Agreement expired at 12:01
a.m., New York City time, on July 10, 2007. At that time, Merger Sub accepted
for payment the shares of Common Stock of the Company or securities
exchangeable, exercisable or convertible into Common Stock that Perseus-Soros
has tendered pursuant to the Offer (collectively, the "Tendered Securities").
CUSIP NO. 09059N100 Page 12 of 15
SCHEDULE 13D
In accordance with the Merger Agreement, Perseus-Soros surrendered its Tendered
Securities in exchange for consideration equal to $5.60 per share of Common
Stock and $11.20 per share of Series A Convertible Preferred Stock, plus
payment of accrued but unpaid dividends with respect to such Series A
Convertible Preferred Stock.
Item 5. INTEREST IN SECURITIES OF THE ISSUER.
Item 5 is hereby amended and restated in its entirety as
follows:
In accordance with the Company's Quarterly Report on Form 10-Q
for the quarter ended March 31, 2007, as of May 3, 2007, there were 55,035,739
shares of Common Stock outstanding.
(a) Pursuant to Rule 13d-3 of the Exchange Act, each of the
Reporting Persons may be deemed the beneficial owner of 75,009 shares of Common
Stock issuable upon the exercise of the May Warrants held for the account of
Perseus-Soros, which constitutes 0.001% of the total number of shares of Common
Stock outstanding.
(b) By virtue of the relationships between and among the
Reporting Persons described in Item 2 of the Initial Statement and as a result
of the provisions of the Voting Agreement, each of the Reporting Persons may be
deemed to have shared power to direct the voting and disposition of the 75,009
shares of Common Stock beneficially owned by Perseus-Soros, assuming the
exercise of the May Warrants held for the account of Perseus-Soros.
(c) On July 10, 2007, as a result of the consummation of the
Offer pursuant to the Merger Agreement and Voting Agreement described in Item 4
above, Merger Sub accepted for payment (A) 3,375,004 shares of Common Stock
held for the account of Perseus-Soros, and (B) 2,250,000 shares of the
Company's Series A Preferred Stock held for the account of Perseus-Soros. In
exchange for these Tendered Securities, Perseus-Soros received consideration
from Merger Sub equal to $5.60 per share of Common Stock and $11.20 per share
of Series A Convertible Preferred Stock, plus any accrued but unpaid dividends
with respect to such Series A Convertible Preferred Stock.
(d) The partners of Perseus-Soros have the right to participate
in the receipt of dividends from, or proceeds from the sales of, the shares of
Common Stock or other securities held for the account of Perseus-Soros in
accordance with their ownership interests in Perseus-Soros.
(e) As of July 10, 2007, the Reporting Persons ceased to be the
beneficial owners of more than five percent of the shares of the Common Stock
of the Company.
CUSIP NO. 09059N100 Page 13 of 15
SCHEDULE 13D
Item 6. CONTRACTS, ARRANGEMENTS, UNDERSTANDINGS OR RELATIONSHIPS WITH
RESPECT TO SECURITIES OF THE ISSUER.
The information in Item 4 is incorporated herein by reference;
otherwise, the information set forth in Item 6 of the Initial Statement remains
unchanged.
Item 7. MATERIAL TO BE FILED AS EXHIBITS.
Exhibit 1: Joint Filing Agreement, dated December 22, 2004,
among (i) Perseus-Soros BioPharmaceutical Fund,
LP, (ii) Perseus-Soros Partners, LLC, (iii)
Perseus BioTech Fund Partners, LLC, (iv) SFM
Participation, L.P., (v) SFM AH LLC, (vi) Frank
H. Pearl, (vii) George Soros, (viii) Soros Fund
Management L.L.C., and (ix) Perseuspur, L.L.C.
(previously filed)
Exhibit 2: Tender and Voting Agreement, dated May 29, 2007,
by and among Genzyme Corporation, a Massachusetts
corporation, Wichita Bio Corporation, a Delaware
corporation and direct or indirect wholly owned
subsidiary of Genzyme Corporation, and
Perseus-Soros BioPharmaceutical Fund, LP
(previously filed)
Exhibit 3: Power of Attorney, dated May 9, 2007, appointing
Kenneth M. Socha and Rona Kennedy as
Attorney-in-Fact for Frank H. Pearl. (previously
filed)
Exhibit 4: Power of Attorney, dated June 16, 2005,
appointing Armando T. Belly, Jodye Anzalotta,
Maryann Canfield, Jay Schoenfarber and Robert
Soros as Attorney-in-Fact for George Soros.
(previously filed)
CUSIP NO. 09059N100 Page 14 of 15
SCHEDULE 13D
SIGNATURE
After reasonable inquiry and to the best of its knowledge and
belief, each of the undersigned certifies that the information set forth in
this statement is true, complete and correct.
Dated: July 12, 2007
PERSEUS-SOROS BIOPHARMACEUTICAL FUND, LP
By: Perseus-Soros Partners, LLC
General Partner
By: SFM Participation, L.P.
Managing Member
By: SFM AH LLC
General Partner
By: Soros Fund Management LLC
Managing Member
By: /s/ Jodye Anzalotta
---------------------------------------
Name: Jodye Anzalotta
Title: Assistant General Counsel
PERSEUS-SOROS PARTNERS, LLC
By: SFM Participation, L.P.
Managing Member
By: SFM AH LLC
General Partner
By: Soros Fund Management LLC
Managing Member
By: /s/ Jodye Anzalotta
---------------------------------------
Name: Jodye Anzalotta
Title: Assistant General Counsel
PERSEUS BIOTECH FUND PARTNERS, LLC
By: Perseuspur, LLC
Managing Member
By: /s/ Rona Kennedy
---------------------------------------
Name: Rona Kennedy
Title: Secretary and Treasurer
PERSEUSPUR, LLC
By: /s/ Rona Kennedy
---------------------------------------
Name: Rona Kennedy
Title: Secretary and Treasurer
CUSIP NO. 09059N100 Page 15 of 15
SCHEDULE 13D
MR. FRANK H. PEARL
By: /s/ Rona Kennedy
---------------------------------------
Name: Rona Kennedy
Title: Attorney-in-Fact
SFM PARTICIPATION, L.P.
By: SFM AH LLC
General Partner
By: Soros Fund Management LLC
Managing Member
By: /s/ Jodye Anzalotta
---------------------------------------
Name: Jodye Anzalotta
Title: Assistant General Counsel
SFM AH LLC
By: Soros Fund Management LLC
Managing Member
By: /s/ Jodye Anzalotta
---------------------------------------
Name: Jodye Anzalotta
Title: Assistant General Counsel
MR. GEORGE SOROS
By: /s/ Jodye Anzalotta
---------------------------------------
Name: Jodye Anzalotta
Title: Attorney-in-Fact
SOROS FUND MANAGEMENT LLC
By: /s/ Jodye Anzalotta
---------------------------------------
Name: Jodye Anzalotta
Title: Assistant General Counsel